Results 31 to 40 of about 406,045 (339)
FOXD3 Regulates VISTA Expression in Melanoma. [PDF]
, 2020 Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of alternative immune targets.
Aplin, Andrew E. +13 more
core +1 more source
Pulmonary Circulation, 2021 Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam +6 more
doaj +1 more source
Clinical & Translational Immunology, 2020 Objectives New targets or strategies are needed to increase the success of immune checkpoint‐based immunotherapy for multiple myeloma (MM). However, immune checkpoint signals in MM microenvironment have not been fully elucidated. Here, we aimed to have a
Jinheng Wang +6 more
doaj +1 more source
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology [PDF]
, 2020 Combination immunotherapy (CIT) is currently applied as a treatment for different cancers and is proposed as a cure strategy for chronic viral infections. Whether such therapies are efficient during an acute infection remains elusive.
Akhmetzyanova, Ilseyar [u.v.m.] +9 more
core +1 more source
Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?
Asian Journal of Urology, 2016 Prostate cancers (PCa) have been reported to actively suppress antitumor immune responses by creating an immune-suppressive microenvironment. There is mounting evidence that PCas may undergo an ‘‘Epithelial Immune Cell-like Transition’’ (EIT) by ...
Dong Lin +5 more
doaj +1 more source
SnapShot: Immune Checkpoint Inhibitors
Cancer Cell, 2017 Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire +4 more sources
Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
Frontiers in Cardiovascular Medicine, 2023 BackgroundImmune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early
Xin Zhang +8 more
doaj +1 more source
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]
, 2017 Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello +3 more
core +1 more source
Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]
Journal of NephropharmacologyImmune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar +4 more
doaj +1 more source
eLifeRadiation therapy is a primary treatment for hepatocellular carcinoma (HCC), but its effectiveness can be diminished by various factors. The over-expression of PD-L1 has been identified as a critical reason for radiotherapy resistance.
Tiesuo Zhao +19 more
doaj +1 more source